Latest Breaking News On - Gram positive selective spectrum - Page 1 : vimarsana.com

Acurx Pharmaceuticals, Inc Reports First Quarter 2024 Results and Provides Business Update

Acurx Pharmaceuticals, Inc Reports First Quarter 2024 Results and Provides Business Update
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesRobertg shawahDavidp luciKevin gareyAcurx pharmaceuticalsInternational cdifficile symposiumEuropean medicines agencyPrnewswire acurx pharmaceuticals incAcurx pharmaceuticals incAnaerobe society of americaDrug administrationInfectious diseases society of americaUniversity of houston college pharmacyEuropean society of microbiologyExchange commission on formMarketing authorization

Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C difficile Infection

Acurx Pharmaceuticals (ACXP) Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C difficile Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobertj delucciaTrial oversight committeeDrug administrationData monitoring committeeAcurx pharmaceuticals incCompany scientific advisory boardAcurx pharmaceuticalsAdvice meetingModified intent to treatClinical cureExecutive chairmanNew drug applicationMarketing authorizationsIbezapolstat phaseScientific advisory board

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.

United statesComunidad autonoma de catalunaKevin gareyEugenie basseresDavidp luciCompany phSociety or healthcare epidemiology of americaGlobal european society of clinical microbiologyTrial oversight committeeData monitoring committeeExchange commission on formInfectious diseases society of americaEuropean society of clinical microbiologyResearch scientistAcurx pharmaceuticalsAcurx pharmaceuticals inc

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.

United statesComunidad autonoma de catalunaKevin gareyEugenie basseresDavidp luciSociety or healthcare epidemiology of americaExchange commissionResearch scientistCompany scientific advisory boardPrnewswire acurx pharmaceuticals incCompany phGlobal european society of clinical microbiologyTrial oversight committeeDrug administrationAcurx pharmaceuticalsUniversity of houston college pharmacy

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical.

United statesComunidad autonoma de catalunaKevin gareyEugenie basseresDavidp luciAcurx pharmaceuticals announces presentation of ibezapolostat phaseUniversity of houston college pharmacyExchange commissionAcurx pharmaceuticals incGlobal european society of clinical microbiologyInfectious diseases society of americaPrnewswire acurx pharmaceuticals incData monitoring committeeResearch scientistTrial oversight committeeExchange commission on form